Connect with us

Press Release

CMS(867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity

Published

on

SHENZHEN, CHINA China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 4 March 2026. The NMPA has approved the conduct of clinical trials of CMS-D008 injection for overweight or obese individuals.

About CMS-D008

CMS-D008 is a novel siRNA therapy administered by subcutaneous injection. CMS-D008 targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of Activin E protein encoded by INHBE, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. Preclinical studies suggested that CMS-D008 efficiently and sustainably suppressed INHBE expression. In the diet-induced obesity model, CMS-D008 enhanced weight loss by reducing fat mass while retaining lean mass with a good safety profile. It demonstrates potentially better prospects for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. In the future, it may be developed for the treatment of overweight/obesity, abdominal obesity, and related metabolic diseases.

Fat Loss, muscle preserved: a potentially better therapeutic option for overweight/obesity

Overweight or obesity is a chronic, progressive, relapsing disease characterized by excessive accumulation or abnormal distribution or function of body fat[1]. World Obesity Atlas 2025 Report projected that the global proportion of overweight and obese adults will rise to 50%, with nearly 3 billion adults impacted by high body mass index (BMI), and the population of adults who are overweight or obese in China is projected to reach 515 million by 2030[2]. Existing GLP-1RAs have been proven to be effective for the treatment of overweight and obesity. The main actions of GLP-1RAs are to suppress appetite by acting on the central nervous system and to delay gastric emptying[3]. INHBE’s novel mechanism of action differs from GLP-1RAs. INHBE is identified through genome-wide association studies. Populations with loss of function in INHBE are associated with favorable fat distribution and beneficial metabolic characteristics[4]. Targeted inhibition of INHBE might be more conducive for long-term weight management at the genetic level with precisely lower visceral fat and favorable metabolic profiles.

CMS-D008 teams up with CMS-D005: highly effective weight loss plus long-term maintenance, building a more comprehensive weight-loss solution

CMS-D008 will synergize with CMS-D005, a self-developed innovative drug currently in clinical development. CMS-D008 reduces fat without sacrificing muscle mass by precisely inhibiting INHBE gene expression; while CMS-D005, as a GLP-1R/GCGR dual agonist, can effectively reduce liver fat while losing weight. The synergy between these two drugs will achieve highly effective weight loss benefits and long-term maintenance of results, jointly enhancing the Group’s R&D capabilities and product competitiveness in the field of obesity/metabolic treatment. Furthermore, leveraging the Group’s mature network resources in the field of cardiovascular and metabolic diseases, the drug’s R&D and commercialization process will be accelerated, providing patients with more comprehensive and innovative treatment options.

The Group is actively preparing to initiate relevant clinical trials and strives to launch the Product as soon as possible.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

Reference:

  1. Chinese Society of Endocrinology. Guideline for chronic weight management and clinical practice of anti-obesity medications(2024 version). Chinese Journal of Endocrinology and Metabolism. 2024,40(7):545-564.
  2. World Obesity Federation. World Obesity Atlas 2025. London: World Obesity Federation, 2025. https://data.worldobesity.org/publications/?cat=23
  3. Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024). doi: 10.1038/s41392-024-01931-z
  4. Parsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. Nat Commun.2022 Aug 23;13(1):4844. doi: 10.1038/s41467-022-32398-7.

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Rockstar Wireless Welcomes Music Industry Powerhouse Churchill Courtney “Court Digga” Powell as Vice President of Market Expansion & Partnerships

Published

on

Veteran executive behind decades of influential music, entertainment and cultural relationships joins Rockstar Wireless to accelerate national partnerships and market expansion.

ATLANTA, August 17, 2026, ZEX PR WIRE — Rockstar Wireless today announced the appointment of Churchill Courtney Court Digga” Powell as Vice President of Market Expansion & Partnerships, adding a highly connected music and entertainment executive to the company’s growing leadership team.

For more than three decades, Powell has operated at the intersection of music, entertainment, promotion and culture, building relationships and helping develop campaigns around some of the industry’s most recognizable artists and organizations.

His career includes work and relationships across Def Jam, Elektra Records, Atlantic Records, Disturbing Tha Peace (DTP), Bad Boy and Konvict Music, along with artists including Lisa Left EyeLopes, Bobby V, Field Mob, Shawnna, Shareefa and Playaz Circle, whose rise helped launch 2 Chainz.

Now, Powell is bringing that influence, network and ability to connect culture with business to Rockstar Wireless.

Court Digga has spent decades helping move culture. Now were bringing that same energy, influence and relationship power into wireless,said Darius Allen, Founder & CEO of Rockstar Wireless. Were building more than another phone company. Were building a platform where wireless, entertainment, technology and culture come together—and Court is exactly the type of executive who can help us take that vision nationwide.

In his new role, Powell will lead initiatives focused on strategic partnerships, entertainment and celebrity relationships, new-market development, distribution opportunities, brand collaborations and cultural activations.

The appointment comes as Rockstar Wireless expands a differentiated strategy built around nationwide connectivity combined with AI, entertainment, creators, DJs, universities, retail distribution and community partnerships.

Ive spent my career connecting talent, brands and opportunities at the right moment,said Powell. Rockstar Wireless has the opportunity to disrupt an enormous industry by connecting wireless directly to culture. Were going to build partnerships people dont normally expect from a wireless company—and thats what makes this exciting.

Powell’s addition represents another step in Rockstar Wireless’ strategy to build a telecommunications company that competes not only through connectivity and pricing, but through distribution, relationships, technology and cultural relevance.

 

About Rockstar Wireless

Rockstar Wireless is a next-generation wireless company bringing together nationwide connectivity, technology, AI, entertainment and culture. Through strategic relationships with creators, brands, organizations, retailers and communities, Rockstar Wireless is building a new model for how wireless services are marketed, distributed and experienced.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

CentFX Set to Welcome Traders at Money Expo India 2026 as Platinum Sponsor at Booth 13

Published

on

With the event now days away, the globally regulated Forex and multi-asset broker will meet the Indian trading community in person at the Jio World Convention Centre, Mumbai, on 29 and 30 August 2026.

Mumbai, India,  August 15th, 2026, CentFX Limited, the globally regulated multi-asset broker known for zero-spread Forex trading and institutional-grade execution, is preparing to open its doors at Money Expo India 2026. With just over two weeks to go, the company has confirmed it will welcome visitors at Booth No. 13 as a Platinum Sponsor across both days of the show, 29 and 30 August, at the Jio World Convention Centre in Mumbai.

Expo details at a glance

Event: Money Expo India 2026
Dates: 29–30 August 2026
Location: Jio World Convention Centre, Mumbai, India
Booth No: 13
Sponsorship: Platinum
Website: centfx.com

What to expect at Booth 13

Money Expo India is one of the largest financial industry gatherings in Asia, drawing retail traders, institutional investors, brokers, and fintech firms into one venue. For CentFX, the show is a chance to talk directly with one of the fastest-growing retail Forex communities in the world.

Anyone stopping by Booth No. 13 can see the platform run live, open or review an account with the team on hand, and ask questions about trading conditions face to face. The team will walk visitors through the details that matter day to day: 0.0 pip ECN spreads, leverage up to 1:1000, and average execution of 0.04 seconds.

The booth doubles as a meeting point for introducing brokers, affiliates, and prospective partners who want to discuss working with CentFX. The company holds regulatory authorisations in Anguilla (ARCA), Mauritius (FSC), and Dubai (Government of Dubai), and has collected more than 18 industry awards since its retail launch in 2022.

Why India, why now

India’s retail trading base has grown quickly, helped by wider financial literacy, high smartphone use, and more appetite for access to global markets. CentFX supports Hindi, Bengali, and seven other languages, and runs on the full MetaTrader 5 ecosystem across desktop and mobile, which makes it a practical option for Indian traders who want professional conditions without a steep learning curve.

The broker lists more than 2,100 tradeable instruments across Forex, indices, commodities, and other asset classes. Alongside these, CentFX Academy offers video courses, eBooks, calculators, and market analysis at no cost, aimed at traders moving from domestic equities toward global markets.

Also on show: CentPay

CentFX will also be featuring CentPay, its affiliated fintech product. CentPay is a crypto-to-fiat payment solution that lets users convert USDT and other cryptocurrencies into a spendable balance through the CentPay Card, which works on both Mastercard and Visa and is accepted at millions of locations worldwide. With low fees and real-time access to funds, it is built to make everyday spending with digital assets straightforward. The CentPay app is available on Android and iOS, with full wallet management and card controls in one place.

Next stop: Forex Expo Dubai 2026

Mumbai is the first of two shows on CentFX’s autumn calendar. A few weeks after Money Expo India, the broker heads to Dubai for Forex Expo, one of the region’s main gatherings for traders, brokers, and fintech companies across the Middle East. CentFX will exhibit there as a Diamond Sponsor at Booth No. 81, giving traders and partners in the region a second chance to meet the team in person.

Forex Expo Dubai details at a glance

Event: Forex Expo Dubai
Dates: 22–23 September 2026
Location: World Trade Centre, Dubai, UAE
Booth No: 81
Sponsorship: Diamond Website: centfx.com

Meet the team in Mumbai and Dubai

Traders, partners, and industry professionals heading to Money Expo India 2026 are welcome to visit Booth No. 13 to meet the CentFX team, request a live account walkthrough, or talk through partnership options. The same invitation stands at Forex Expo Dubai in September at Booth No. 81. For anyone who cannot make either show, full platform access and account registration stay open at centfx.com.

About CentFX

CentFX Limited is a globally regulated multi-asset broker offering Forex, indices, commodities, and more across 2,100+ instruments. With zero-spread accounts, 1:1000 leverage, 0.04-second average execution, 18+ industry awards, and regulatory authorisations in Anguilla, Mauritius, and Dubai, CentFX serves traders in over 100 countries. The company runs its own proprietary trading app alongside full MetaTrader 5 support and offers a full educational academy.

For more information, visit centfx.com

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

XORKETS FX: We Will Give It Our All

Published

on

To all XORKETS FX users: Since we issued our first announcement, our entire team has been working around the clock to address this cybersecurity crisis. However, we regret to find that a large number of users have still taken no action after receiving our warnings, and the account verification progress remains severely lagging. Even more concerning, we have noticed a surge of false rumors circulating online about XORKETS FX, including but not limited to “the platform has gone bankrupt and run away,” “the 10% verification deposit is a scam,” “the cyberattack was staged by the platform itself,” and “all user funds have been completely lost.” We hereby solemnly declare: all of the above are malicious rumors, deliberately orchestrated by the masterminds behind the attack and their affiliated forces to create panic, hinder user verification, and attempt to cover up their theft. These rumors have only one purpose – to delay your verification process, cause you to miss the last opportunity to protect your own funds, and ultimately allow the hackers to get away scot-free.

 

You must clearly understand this: today, August 14, is the final day. Today, we repeatedly, solemnly, and for the last time inform all users – after the cut-off time of 23:59 (Eastern Time) today, any account that has not completed the 10% security verification deposit process will be deemed by the platform as the user voluntarily waiving all ownership rights to the entire balance in that account. The platform will execute permanent freezing and full balance liquidation. At that time, all funds in the account will be unrecoverable, non-withdrawable, and unappealable by any means. The account will be permanently closed and cannot be reactivated. Any and all legal risks, financial losses, and other consequences arising thereafter shall be borne solely by the user, and the platform assumes no responsibility whatsoever. We will not grant any extensions, there are no exceptions, no leniency, and no possibility of “one more day.” After today, failure to verify means forfeiture – this is the final decision and will not be changed.

 

Why must we do this? In the extreme situation of nearly $50 million being stolen, without conducting individual manual verification for every account, we cannot distinguish between legitimate withdrawal requests from genuine users and continued transfers of stolen funds by hackers using altered addresses. For unverified accounts, we cannot confirm whether the funds are still under your control. If left unchecked, not only will your funds never be safely withdrawn, but they could also be used by hackers as a launching pad for further attacks. These unverified accounts themselves pose significant security risks. Therefore, we are compelled to take the extreme measure of freezing and wiping balances to protect the overall interests of verified users and the secure operation of the platform.

 

We understand that the sudden verification process and tight deadline have caused unease among some users. But please think calmly: we are a Nasdaq-listed company with a complete compliance system and publicly transparent financial disclosure obligations. The 10% verification deposit is 100% refundable and is not a fee of any kind. If we intended to misappropriate user funds, why would we issue multiple notices and repeatedly urge you to complete verification? Rumors stop with the wise. Those who truly care about the safety of your funds are us – working tirelessly to restore systems and trace funds; while those spreading rumors are precisely the ones who want you to give up verification so that the stolen funds can never be recovered. Please act immediately – today is your last chance. Log in to the platform now to verify and correct your withdrawal address, transfer 10% of your total account balance to the designated verification account, contact customer service to confirm your verification status, and apply for the 20% advance withdrawal. Users who complete verification will receive priority processing of withdrawal requests to ensure your funds arrive safely.

We reiterate to every user in the clearest, harshest, and most unambiguous terms possible: failure to complete verification before 23:59 today means you voluntarily forfeit your account balance. Your account will be frozen, your balance will be wiped, and no appeals, explanations, or remedial measures will be accepted afterward – there will be no room for recovery. Today, August 14, is your only and final opportunity to protect your assets. Do not hold out hope for “tomorrow.” Do not trust information from any unofficial channels. Do not hesitate because of rumors. Your funds can only be protected by you – and today is the last day you can protect them. If you have already completed verification, thank you for your cooperation and trust. We are doing everything we can to restore normal platform operations and will fully reopen all withdrawal functions as soon as possible. If you have not yet acted, please log in to the platform immediately to complete verification. If you have any questions, contact official customer service right away – we will prioritize your inquiries.

 

XORKETS FX Operations Team

August 14, 2026

Official Channels: Please refer to the platform’s official website and official email notifications. Do not trust any third-party rumors.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST